Stocktoria
Maze Therapeutics, Inc. MAZE
Maze Therapeutics, Inc. (MAZE) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.824 |
| Retained earnings / assets | -1.233 |
| EBIT / assets | -0.36 |
| Equity / liabilities | 8.419 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | 2/9 | 7.81 | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
FAQ
Is MAZE financially healthy?
Maze Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MAZE pay a dividend?
No, Maze Therapeutics, Inc. does not currently pay a dividend.
How profitable is MAZE?
In FY2025, Maze Therapeutics, Inc. had a return on equity of -36.9%.
What is the analyst price target for MAZE?
The average Wall-Street price target for Maze Therapeutics, Inc. is $62.55, about 127.2% above the recent price, from 11 analysts (consensus: strong buy).
Is MAZE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Maze Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.